Pfizer (NYSE:PFE) had its price objective raised by investment analysts at Morgan Stanley from $41.00 to $43.00 in a research report issued on Wednesday, January 31st, MarketBeat reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price indicates a potential upside of 27.86% from the stock’s current price.

PFE has been the subject of several other reports. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a research note on Friday, October 6th. JPMorgan Chase & Co. set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Wednesday, November 1st. Jefferies Group set a $39.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Thursday, November 16th. Nord/LB reaffirmed a “neutral” rating on shares of Pfizer in a research note on Tuesday, January 2nd. Finally, Berenberg Bank set a $36.00 price objective on Pfizer and gave the company a “neutral” rating in a research note on Tuesday, October 31st. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $39.45.

Pfizer (NYSE PFE) traded down $1.35 on Wednesday, hitting $33.63. The stock had a trading volume of 43,496,972 shares, compared to its average volume of 23,070,000. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. The firm has a market cap of $200,460.00, a PE ratio of 9.55, a P/E/G ratio of 2.12 and a beta of 0.94. Pfizer has a 1-year low of $31.67 and a 1-year high of $39.43.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The firm had revenue of $13.70 billion during the quarter, compared to the consensus estimate of $13.67 billion. During the same period last year, the business posted $0.47 EPS. Pfizer’s quarterly revenue was up .6% on a year-over-year basis. sell-side analysts expect that Pfizer will post 2.95 EPS for the current fiscal year.

Pfizer declared that its board has authorized a stock repurchase program on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

In other news, insider Alexander R. Mackenzie sold 6,750 shares of Pfizer stock in a transaction on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now owns 103,458 shares of the company’s stock, valued at $3,827,946. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Rady A. Johnson sold 8,000 shares of Pfizer stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the sale, the executive vice president now directly owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. Company insiders own 0.06% of the company’s stock.

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Pfizer by 4.4% in the third quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after acquiring an additional 2,502,659 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Pfizer by 0.9% in the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after acquiring an additional 389,629 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Pfizer by 4.8% in the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after acquiring an additional 2,028,313 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its holdings in Pfizer by 3.6% in the fourth quarter. Fisher Asset Management LLC now owns 36,372,349 shares of the biopharmaceutical company’s stock valued at $1,317,407,000 after acquiring an additional 1,251,550 shares during the last quarter. 69.87% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was first posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.dailypolitical.com/2018/02/02/pfizer-pfe-pt-set-at-43-00-by-morgan-stanley.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.